Current trends in the management of Richter's syndrome

por Allan, John N, Furman, Richard R
Publicado 2019

Recurrent Gastrointestinal Near-Tetraploid Diffuse Large B-Cell Lymphoma Causing Intussusception and Ileal Ulceration

por Mathews, Steven N., Niec, Rachel, Mathew, Susan, Allan, John N., Crawford, Carl V.
Publicado 2019

Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials

por Allan, John N., Shanafelt, Tait, Wiestner, Adrian, Moreno, Carol, O’Brien, Susan M., Li, Jianling, Krigsfeld, Gabriel, Dean, James P., Ahn, Inhye E.
Publicado 2021

Targeting metabolism and survival in chronic lymphocytic leukemia and Richter syndrome cells by a novel NF-κB inhibitor

por Vaisitti, Tiziana, Gaudino, Federica, Ouk, Samedy, Moscvin, Maria, Vitale, Nicoletta, Serra, Sara, Arruga, Francesca, Zakrzewski, Johannes L., Liou, Hsiou-Chi, Allan, John N., Furman, Richard R., Deaglio, Silvia
Publicado 2017

Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib

por SahBandar, Ivo N., Sy, Chandler B., van den Akker, Tayler, Kim, David, Geyer, Julia T., Chadburn, Amy, Cesarman, Ethel, Inghirami, Giorgio, Allan, John N., Siddiqui, Momin T., Ouseph, Madhu M.
Publicado 2023

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

por Barr, Paul M., Tedeschi, Alessandra, Wierda, William G., Allan, John N., Ghia, Paolo, Vallisa, Daniele, Jacobs, Ryan, O'Brien, Susan, Grigg, Andrew P., Walker, Patricia, Zhou, Cathy, Ninomoto, Joi, Krigsfeld, Gabriel, Tam, Constantine S.
Publicado 2022

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy

por Arruga, Francesca, Rubin, Marta, Papazoglou, Despoina, Iannello, Andrea, Ioannou, Nikolaos, Moia, Riccardo, Rossi, Davide, Gaidano, Gianluca, Coscia, Marta, Laurenti, Luca, D’Arena, Giovanni, Allan, John N., Furman, Richard R., Vaisitti, Tiziana, Ramsay, Alan G., Deaglio, Silvia
Publicado 2023

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia

por Rogers, Kerry A., Thompson, Philip A., Allan, John N., Coleman, Morton, Sharman, Jeff P., Cheson, Bruce D., Jones, Daniel, Izumi, Raquel, Frigault, Melanie M., Quah, Cheng, Raman, Rakesh K., Patel, Priti, Wang, Min Hui, Kipps, Thomas J.
Publicado 2021

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

por Allan, John N., Flinn, Ian W., Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S., Kipps, Thomas J., Barr, Paul M., Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C., Jacobs, Ryan, Kuss, Bryone J., Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G.
Publicado 2023

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

por Ujjani, Chaitra, Mato, Anthony, Hill, Brian T, Allan, John N, Lansigan, Frederick, Jacobs, Ryan, Skarbnik, Alan, Tuncer, Hande, Pagel, John, Brander, Danielle, Cheson, Bruce, Barr, Paul, Roeker, Lindsey E, Pu, Jeffrey, Shah, Nirav N, Goy, Andre, Schuster, Stephen J, Lamanna, Nicole, Sehgal, Alison, Tam, Constantine S, Shadman, Mazyar
Publicado 2020

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAP...

por Wierda, William G., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Opat, Stephen, Tedeschi, Alessandra, Badoux, Xavier C., Kuss, Bryone J., Jackson, Sharon, Moreno, Carol, Jacobs, Ryan, Pagel, John M., Flinn, Ian, Pak, Yvonne, Zhou, Cathy, Szafer-Glusman, Edith, Ninomoto, Joi, Dean, James P., James, Danelle F., Ghia, Paolo, Tam, Constantine S.
Publicado 2021

Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

por Allan, John N., Pinilla-Ibarz, Javier, Gladstone, Douglas E., Patel, Krish, Sharman, Jeff P., Wierda, William G., Choi, Michael Y., O’Brien, Susan M., Shadman, Mazyar, Davids, Matthew S., Pagel, John M., Yimer, Habte A., Ward, Renee, Acton, Gary, Taverna, Pietro, Combs, Daniel L., Fox, Judith A., Furman, Richard R., Brown, Jennifer R.
Publicado 2021

Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL

por Pastore, Alessandro, Gaiti, Federico, Lu, Sydney X., Brand, Ryan M., Kulm, Scott, Chaligne, Ronan, Gu, Hongcang, Huang, Kevin Y., Stamenova, Elena K., Béguelin, Wendy, Jiang, Yanwen, Schulman, Rafael C., Kim, Kyu-Tae, Alonso, Alicia, Allan, John N., Furman, Richard R., Gnirke, Andreas, Wu, Catherine J., Melnick, Ari M., Meissner, Alexander, Bernstein, Bradley E., Abdel-Wahab, Omar, Landau, Dan A.
Publicado 2019

Venetoclax in Previously Treated Waldenström Macroglobulinemia

por Castillo, Jorge J., Allan, John N., Siddiqi, Tanya, Advani, Ranjana H., Meid, Kirsten, Leventoff, Carly, White, Timothy P., Flynn, Catherine A., Sarosiek, Shayna, Branagan, Andrew R., Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Xu, Lian, Yang, Guang, Patterson, Christopher J., Hunter, Zachary R., Davids, Matthew S., Furman, Richard R., Treon, Steven P.
Publicado 2022

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies

por Chong, Stephen Jun Fei, Zhu, Fen, Dashevsky, Olga, Mizuno, Rin, Lai, Jolin X.H., Hackett, Liam, Ryan, Christine E., Collins, Mary C., Iorgulescu, J. Bryan, Guièze, Romain, Penailillo, Johany, Carrasco, Ruben, Hwang, Yeonjoo C., Muñoz, Denise P., Bouhaddou, Mehdi, Lim, Yaw Chyn, Wu, Catherine J., Allan, John N., Furman, Richard R., Goh, Boon Cher, Pervaiz, Shazib, Coppé, Jean-Philippe, Mitsiades, Constantine S., Davids, Matthew S.
Publicado 2023

Epigenetic evolution and lineage histories of chronic lymphocytic leukemia

por Gaiti, Federico, Chaligne, Ronan, Gu, Hongcang, Brand, Ryan Matthew, Kothen-Hill, Steven, Schulman, Rafael, Grigorev, Kirill, Risso, Davide, Kim, Kyu-Tae, Pastore, Alessandro, Huang, Kevin Y., Alonso, Alicia, Sheridan, Caroline, Omans, Nathaniel D., Biederstedt, Evan, Clement, Kendell, Wang, Lili, Felsenfeld, Joshua A., Bhavsar, Erica B., Aryee, Martin J., Allan, John N., Furman, Richard, Gnirke, Andreas, Wu, Catherine J., Meissner, Alexander, Landau, Dan A.
Publicado 2019

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia

por Eyre, Toby A., Lamanna, Nicole, Roeker, Lindsey E., Ujjani, Chaitra S, Hill, Brian T., Barr, Paul M., Lansigan, Erick, Cheson, Bruce D., Yazdy, Maryam, Allan, John N., Rhodes, Joanna, Schuster, Stephen J., Nabhan, Chadi, Skarbnik, Alan, Leslie, Lorie, Islam, Prioty, Whitaker, Katherine, Coombs, Catherine C., Tuncer, Hande H., Pagel, John M., Jacobs, Ryan, Winter, Allison M., Bailey, Neil, Sitlinger, Andrea, Schuh, Anna H., Follows, George, Fox, Christopher P., Brander, Danielle M., Shadman, Mazyar, Mato, Anthony R.
Publicado 2020

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

por Davids, Matthew S., O’Connor, Owen A., Jurczak, Wojciech, Samaniego, Felipe, Fenske, Timothy S., Zinzani, Pier Luigi, Patel, Manish R., Ghosh, Nilanjan, Cheson, Bruce D., Derenzini, Enrico, Brander, Danielle M., Reeves, James A., Knopińska-Posłuszny, Wanda, Allan, John N., Phillips, Tycel, Caimi, Paolo F., Lech-Maranda, Ewa, Burke, John M., Agajanian, Richy, Pettengell, Ruth, Leslie, Lori A., Cheah, Chan Y., Fonseca, Gustavo, Essell, James, Chavez, Julio C., Pagel, John M., Sharman, Jeff P., Hsu, Yanzhi, Miskin, Hari P., Sportelli, Peter, Weiss, Michael S., Flinn, Ian W.
Publicado 2021

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

por Thompson, Meghan C., Harrup, Rosemary A., Coombs, Catherine C., Roeker, Lindsey E., Pu, Jeffrey J., Choi, Michael Y., Barr, Paul M., Allan, John N., Šimkovič, Martin, Leslie, Lori, Rhodes, Joanna, Chong, Elise A., Kamdar, Manali, Skarbnik, Alan, Lansigan, Frederick, McCall, Brittany, Saja, Khalid, Dyer, Martin J.S., Walter, Harriet S., Lefebure, Marcus, Thadani-Mulero, Maria, Boyer, Michelle, Biondo, Juliana, Sail, Kavita, Manzoor, Beenish S., Furman, Richard, Bantilan, Kurt S., Goy, Andre, Feldman, Tatyana, Labella, Dominic, Schuster, Stephen J., Park, Jae, Palomba, Lia, Zelenetz, Andrew, Eyre, Toby A., Kater, Arnon P., Seymour, John F., Mato, Anthony R.
Publicado 2022

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEM...

por Cuneo, Antonio, Mato, Anthony R., Rigolin, Gian Matteo, Piciocchi, Alfonso, Gentile, Massimo, Laurenti, Luca, Allan, John N., Pagel, John M., Brander, Danielle M., Hill, Brian T., Winter, Allison, Lamanna, Nicole, Tam, Constantine S., Jacobs, Ryan, Lansigan, Frederick, Barr, Paul M., Shadman, Mazyar, Skarbnik, Alan P., Pu, Jeffrey J., Sehgal, Alison R., Schuster, Stephen J., Shah, Nirav N., Ujjani, Chaitra S., Roeker, Lindsey, Orlandi, Ester Maria, Billio, Atto, Trentin, Livio, Spacek, Martin, Marchetti, Monia, Tedeschi, Alessandra, Ilariucci, Fiorella, Gaidano, Gianluca, Doubek, Michael, Farina, Lucia, Molica, Stefano, Di Raimondo, Francesco, Coscia, Marta, Mauro, Francesca Romana, de la Serna, Javier, Medina Perez, Angeles, Ferrarini, Isacco, Cimino, Giuseppe, Cavallari, Maurizio, Cucci, Rosalba, Vignetti, Marco, Foà, Robin, Ghia, Paolo
Publicado 2020